Kymera Therapeutics Inc (KYMR) - Total Assets
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) holds total assets worth $1.67 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Kymera Therapeutics Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Kymera Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See what is Kymera Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Kymera Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kymera Therapeutics Inc's total assets of $1.67 Billion consist of 50.0% current assets and 50.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KYMR stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kymera Therapeutics Inc's current assets represent 50.0% of total assets in 2025, a decrease from 94.5% in 2018.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 93.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kymera Therapeutics Inc Competitors by Total Assets
Key competitors of Kymera Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Kymera Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.81 | 8.49 | 3.36 |
| Quick Ratio | 10.81 | 8.49 | 3.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $614.79 Million | $441.96 Million | $256.12 Million |
Kymera Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Kymera Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.07 |
| Latest Market Cap to Assets Ratio | 4.88 |
| Asset Growth Rate (YoY) | 78.2% |
| Total Assets | $1.74 Billion |
| Market Capitalization | $8.51 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kymera Therapeutics Inc's assets at a significant premium (4.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kymera Therapeutics Inc's assets grew by 78.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Kymera Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.74 Billion | +78.20% |
| 2024-12-31 | $978.03 Million | +69.87% |
| 2023-12-31 | $575.76 Million | -4.54% |
| 2022-12-31 | $603.13 Million | -0.46% |
| 2021-12-31 | $605.90 Million | +24.37% |
| 2020-12-31 | $487.18 Million | +317.45% |
| 2019-12-31 | $116.70 Million | +163.85% |
| 2018-12-31 | $44.23 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more